Table 4.

Comparison of the estimated association of induction treatments on overall allograft failure using multivariable Cox regression models

Induction TypeOverall Graft Failure within 5 yr of Transplant, %HRa95% CIP Value
Steroid
 Cox regressiona
  IL2-RA25.91
  r-ATG25.80.980.93 to 1.030.35
  Alemtuzumab25.71.060.94 to 1.190.33
  No induction28.11.010.95 to 1.070.84
 PS–weighted Cox regressionb
  IL2-RA25.91
  r-ATG25.80.970.93 to 1.020.29
  Alemtuzumab25.70.990.89 to 1.100.84
  No induction28.11.000.94 to 1.060.98
No steroid
 Cox regressiona
  IL2-RA27.41
  r-ATG23.10.840.73 to 0.96<0.01
  Alemtuzumab26.20.900.78 to 1.040.15
 PS–weighted Cox regressionb
  IL2-RA27.41
  r-ATG23.10.860.75 to 0.990.03
  Alemtuzumab26.20.930.81 to 1.080.36
  • HR, hazard ratio; 95% CI, 95% confidence interval; IL2-RA, IL-2 receptor antagonist; r-ATG, rabbit antithymocyte globulin; PS, propensity score.

  • a Adjusted for donor factors (sex and kidney donor profile index), recipient factors (age, sex, race, diabetes status, cardiovascular disease, panel reactive antibody, retransplant status, and dialysis exposure), transplant factors (cold ischemia time, donor-to-recipient weight ratio, HLA mismatch, and transplant year), transplant center, and the Organ Procurement and Transplantation Network region.

  • b PS weighted and adjusted for transplant center and the Organ Procurement and Transplantation Network region.